A primary risk associated with surgery comes not from the operation itself, but the risk of infection afterwards. The sutures left in place give pathogens easy access to the wound, often forming shells that are very difficult to remove known as biofilms. To combat this, many sutures are coated in antibiotics like Triclosan. While Triclosan may reduce pathogenic colonization for a short time, biofilms can form, limiting their effectiveness, leading to them having no impact on pre-established biofilms. Beyond the financial burden placed on healthcare systems, surgical site infections, or SSIs, negatively impact patients’ quality of life, extending hospital stays, delaying recovery time, and increasing morbidity rates. Biofilms are not entirely impervious to attack though. In nature, bacteriophages use an enzyme called depolymerase to kill bacteria by breaking down the biofilms that protect them. Our project proposes transforming the genetic code for a phage derived depolymerase, DpoMK34, into Escherichia coli for protein production. The product would then be purified using histidine tagging before being used to coat the sutures, preventing biofilms from forming. By targeting the mechanisms underlying biofilm formation, rather than relying on traditional antibiotics, enzyme based antimicrobial sutures can reduce SSIs while minimizing cost and health risks.